Healthcare >> CEO Interviews >> June 2, 2004
MARTIN STEPHEN GERSTEL is Chairman of Compugen Ltd., a life science
discovery company, and co-Founder/co-Chairman of Itamar Medical, a
medical device company, both headquartered in Israel. Prior to
relocating to Israel in 1994, Mr. Gerstel was the co-Chairman and CEO of
ALZA Corporation, a pharmaceutical company based on advanced drug
delivery mechanisms, where he had participated in the founding in 1968
and subsequently held a series of senior management positions including
CFO, COO and CEO. ALZA was purchased by Johnson & Johnson in 2001. In
addition to his activities with Compugen and Itamar Medical, Mr. Gerstel
currently serves as a Director of Symyx Technologies and the Foundation
for the National Medals of Science and Technology; is a member of the
Board of Governors and the Executive Committee of the Weizmann Institute
of Science and the Board of Governors of the Hebrew University, and is
an Advisor to the Burrill Life Science Funds and the Board of the
Israel-U.S. Binational Industrial Research and Development (BIRD)
Foundation. He also is a frequent lecturer and seminar leader in various
areas of corporate management and strategy, negotiations and finance.
Mr. Gerstel is a graduate of Yale University and the Stanford Graduate
School of Business. Profile
of your operation?
Mr. Gerstel: Compugen is a drug and diagnostic discovery company and is
a leader in incorporating
